Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease.
Re-challenge
interstitial lung disease (ILD)
platinum and etoposide
sensitive relapse
small-cell lung cancer (SCLC)
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
ppublish
Résumé
Treatment modalities for small-cell lung cancer (SCLC) with pre-existing interstitial lung disease (ILD) are limited. Although re-challenge with first-line chemotherapy can be effective for sensitive relapse SCLC, its safety and efficacy are uncertain in cases with ILD. This study aimed to investigate both the efficacy and safety of re-challenge chemotherapy in patients with sensitive relapse SCLC with ILD. Patients with sensitive relapse SCLC with ILD who received re-challenge chemotherapy were studied retrospectively. Sensitive relapse was defined as a treatment-free interval (TFI) of more than 60 days after first-line platinum-based treatment. The endpoints were progression-free survival (PFS), overall survival (OS), and safety. Re-challenge platinum and etoposide were administered in 11 patients, with the median re-challenge cycle of 3. The overall response rate was 55%. The median PFS and OS from the time of re-challenge treatment were 4 months (95% CI, 2.9-NA) and 9.2 months (95% CI, 8.0-NA), respectively. One patient developed acute exacerbation of ILD 173 days after the last course of re-challenge treatment. Re-challenge chemotherapy can be effective and considered in SCLC patients with pre-existing ILD.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment modalities for small-cell lung cancer (SCLC) with pre-existing interstitial lung disease (ILD) are limited. Although re-challenge with first-line chemotherapy can be effective for sensitive relapse SCLC, its safety and efficacy are uncertain in cases with ILD. This study aimed to investigate both the efficacy and safety of re-challenge chemotherapy in patients with sensitive relapse SCLC with ILD.
METHODS
METHODS
Patients with sensitive relapse SCLC with ILD who received re-challenge chemotherapy were studied retrospectively. Sensitive relapse was defined as a treatment-free interval (TFI) of more than 60 days after first-line platinum-based treatment. The endpoints were progression-free survival (PFS), overall survival (OS), and safety.
RESULTS
RESULTS
Re-challenge platinum and etoposide were administered in 11 patients, with the median re-challenge cycle of 3. The overall response rate was 55%. The median PFS and OS from the time of re-challenge treatment were 4 months (95% CI, 2.9-NA) and 9.2 months (95% CI, 8.0-NA), respectively. One patient developed acute exacerbation of ILD 173 days after the last course of re-challenge treatment.
CONCLUSIONS
CONCLUSIONS
Re-challenge chemotherapy can be effective and considered in SCLC patients with pre-existing ILD.
Identifiants
pubmed: 30962995
doi: 10.21037/jtd.2019.01.26
pii: jtd-11-02-514
pmc: PMC6409263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
514-520Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Radiology. 1999 May;211(2):555-60
pubmed: 10228542
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Clin Oncol. 2006 Dec 1;24(34):5441-7
pubmed: 17135646
Radiology. 1992 Feb;182(2):337-42
pubmed: 1732946
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Oncol. 2011 Apr;6(4):801-7
pubmed: 21336181
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
Lancet. 2011 Nov 12;378(9804):1741-55
pubmed: 21565397
Anticancer Res. 2013 Mar;33(3):1175-9
pubmed: 23482799
Eur J Cancer. 2014 Sep;50(13):2211-8
pubmed: 24981975
J Clin Oncol. 2014 Dec 10;32(35):4012-9
pubmed: 25385727
Clin Lung Cancer. 2015 Nov;16(6):e223-8
pubmed: 25983005
Lung Cancer. 2015 Jul;89(1):61-5
pubmed: 26004087
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
Lancet Oncol. 2016 Aug;17(8):1147-1157
pubmed: 27312053
Eur J Cancer Clin Oncol. 1987 Sep;23(9):1409-11
pubmed: 2824211
Eur J Cancer Clin Oncol. 1987 Nov;23(11):1697-9
pubmed: 2828074
Med Oncol. 2018 Apr 2;35(5):61
pubmed: 29610997
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
J Clin Oncol. 1997 May;15(5):2090-6
pubmed: 9164222